Académique Documents
Professionnel Documents
Culture Documents
bioprognos
UNKNOWN PRIMARY STATISTICS
Global
The exact number of Cancers of Unknown Primary (CUP) diagnosed each year is unknown, because
some cancers start out being diagnosed as Unknown Primary, but the primary site is found later. Still,
the American Cancer Society estimates that about 33,770 cases of cancer of unknown primary will be
diagnosed in 2017 in the United States.
This number represents about 2% of all cancers. As more sophisticated lab tests become available to
determine where a cancer started, the number of cancers of unknown primary may go down.
8.2%
The prognosis for patients with Cancer of Unknown Primary is very poor. As a group, the median survival is
approximately 3 months with less than 25% and 10% of patients alive at 1 and 5 years, respectively.
Cancer of Unknown Primary is represented by a heterogeneous group of diseases all of which have presented
with metastasis as the primary manifestation. In each instance, distinct clinical and pathologic details require
consideration for appropriate, potentially curative, management.
Although only a minority of patients will have curable disease or a disease for which there is substantial
palliative benefit, the appropriate use of special diagnostic pathology will identify patients for whom directed
therapy will provide the best possible chance for response.
All these diagnostic tests and complementary examinations to which will be submitted to the patient,
are intended to determining the primary tumor to be treated in the most suitable way, something that
unfortunately wont be achieved in most cases, which results in high stress levels, as well a very
substantial economic costs.
For this reason, in most cases the number of scans are limited to those that can provide a clinical benefit
to the patient, because currently, the treatment of patients with Carcinoma of Unknown Origin has a very
poor prognosis and provides meager profits, what recommends to focus all effors in determine which
chemotherapy scheme can provide the maximum benefit with minimal toxicity.
DIAGNOSIS REVOLUTION
OncoCUP is based in a simple blood test that can detect Unknown Primary Cancer with 82.4% of
sensibility and 98.1% of specificity.
OncoCUP reduces in a very significantly way, the number of false positives (FP) and false negatives
(FN) typical of other diagnosis procedures.
OncoCUP can reduce the number of unnecessary tissue biopsies that patients have to undergo when
suspicious finding.
OncoCUP has been performed with data from 4.610 consecutive patients, then fine-tuned by other
research.
WHY CHOOSE BIOPROGNOS TEST?
Innovative
Based on the combined count of AFP, -hCG, CA 15.3, CA 19.9, CA 72.4, CA 125, CEA, CYFRA, HE4,
NSE, ProGRP, PSA, fPSA, SCC and S100 Tumor Markers.
Non-invasive
First simple blood based test.
Accurate
Very high diagnostic capabilities: 82.4% Sensitivity and 98.1% Specificity.
Cost-effective
Solution to help in Unknown Primary Cancer diagnosis reducing the number of procedures that patients
have to undergo.
More complete
Besides Unknown Primary Cancer it also can determine the primary site.
Already validated
CE Declaration of Conformity reached (According to Annex VII of Medical Device Directive 93/42/EEC).
Patients with cancer found in one or more metastatic sites but the primary site cannot be determined.
USES AND PURPOSES
Confirm or discard malignancy from results obtained previously with other tests, such as Computed
Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) findings thanks higher Sensitivity and
Specificity than imaging procedures.
Guide treatment decisions (such as decide whether to add or immunotherapy after surgery and/or
radiation therapy), therapy monitoring (doctors may use changes in the presence or amount of one or
more Tumor Markers to assess how the cancer is responding to treatment) and predict or monitor for
recurrence (looking for changes in the amount of a Tumor Marker may be part of their follow-up care
plan and may help detect a recurrence sooner than other methods).
INTERPRETATION OF RESULTS
Once the blood is analyzed and the Tumor Marker values are calculated, a final report wirh the probability of
finding Unknown Primary Cancer is generated.
This report includes all patient information previously collected, results, comments if available, as well as
conclusions. It also includes a comprehensive 3 level color score bar to facilitate test interpretation in an easy
way, which can result in Negative, Low Positive and High Positive as follows:
Negative: There is a very low risk of Unknown Primary Cancer, with a probability of 99.9% and it is
recommended to repeat the test in one year due to low risk of malignancy.
Low Positive: There is a certain chance of Unknown Primary Cancer that does not allow to exclude
malignancy. The specialist will decide what further steps to follow. Of every three individuals with
Positive Low result, 1 will present Unknown Primary Cancer.
High Positive: There is a very high risk of Unknown Primary Cancer, with a probability of 99.9%.
bioprognos
Bioprognos SL
Milanesat, 12
08017 Barcelona, SPAIN
www.bioprognos.com
support@bioprognos.com